Last reviewed · How we verify
GSK plc — Portfolio Competitive Intelligence Brief
GSK (NYSE)
57 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Exdensur | DEPEMOKIMAB | marketed | Histamine | Respiratory | 2025-01-01 | |
| Blujepa | GEPOTIDACIN | marketed | Infectious Disease | 2025-01-01 | ||
| Jesduvroq | DAPRODUSTAT | marketed | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] | Egl nine homolog 1 | Hematology | 2023-01-01 |
| Brexafemme | IBREXAFUNGERP | marketed | Triterpenoid Antifungal | Infectious Disease | 2021-01-01 | |
| Jemperli | DOSTARLIMAB | marketed | Programmed Death Receptor-1 Blocking Antibody [EPC] | PD-1 | Oncology | 2021-01-01 |
| Vocabria | CABOTEGRAVIR | marketed | Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor | Immunology | 2021-01-01 | |
| Brexafemme | IBREXAFUNGERP CITRATE | marketed | Triterpenoid Antifungal | Infectious Disease | 2021-01-01 | |
| Blenrep | BELANTAMAB MAFODOTIN | marketed | BCMA | Oncology | 2020-01-01 | |
| Rukobia | FOSTEMSAVIR | marketed | Potassium voltage-gated channel subfamily H member 2 | Immunology | 2020-01-01 | |
| Nuceiva | BOTULINUM TOXIN TYPE A | marketed | Acetylcholine Release Inhibitor [EPC] | Synaptosomal-associated protein 25 | Neuroscience | 2019-01-01 |
| Zejula | niraparib | marketed | Poly(ADP-Ribose) Polymerase Inhibitor | Poly [ADP-ribose] polymerase 2 | Oncology | 2017-01-01 |
| Nucala | MEPOLIZUMAB | marketed | Interleukin-5 Antagonist [EPC] | Interleukin-5 | Respiratory | 2015-01-01 |
Therapeutic area mix
- Immunology · 17
- Metabolic · 7
- Neuroscience · 6
- Infectious Disease · 6
- Other · 5
- Oncology · 5
- Respiratory · 4
- Cardiovascular · 3
- Rare Disease · 2
- Hematology · 1
Recent regulatory actions (last 90 days)
- — Flonase · FDA · approved · US
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Flonase · 7500444*PED · Compound · US
- — Lamictal · 8637512 · Formulation · US
- — Zofran · 8580830 · Formulation · US
- — Imitrex · 10603305 · Formulation · US
- — Imitrex · 9974770 · Formulation · US
- — Imitrex · 9610280 · Formulation · US
- — Imitrex · 11337962 · Formulation · US
- — Imitrex · 12090139 · Formulation · US
- — Zofran · 9095577 · Formulation · US
- — Flonase · 10195375 · Formulation · US
- — Flonase · 12083270 · Method of Use · US
- — Imitrex · 9211282 · Formulation · US
- — Flonase · 10195375*PED · Compound · US
- — Flonase · 10918816 · Formulation · US
- — Flonase · 11554229 · Method of Use · US
- — Flonase · 10918816*PED · Compound · US
- — Flonase · 11969544 · Formulation · US
- — Flonase · 11344685 · Formulation · US
- — Flonase · 11969544*PED · Compound · US
- — Flonase · 11344685*PED · Compound · US
- — Lamictal · 11612566 · Method of Use · US
- — Lamictal · 11596634 · Method of Use · US
- — Flonase · 11173259 · Formulation · US
- — Flonase · 11173259*PED · Compound · US
Competitive overlap (companies sharing drug classes)
- · 8 shared drug classes
- Bristol-Myers Squibb · 4 shared drug classes
- Pfizer · 3 shared drug classes
- London School of Hygiene and Tropical Medicine · 2 shared drug classes
- Baxter · 2 shared drug classes
- Merck Sharp & Dohme LLC · 2 shared drug classes
- GlaxoSmithKline · 2 shared drug classes
- Sanofi · 2 shared drug classes
Subscribe to ongoing alerts
Every new pipeline event for GSK plc:
Cite this brief
Drug Landscape (2026). GSK plc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gsk. Accessed 2026-05-13.